<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514083</url>
  </required_header>
  <id_info>
    <org_study_id>150172</org_study_id>
    <secondary_id>15-H-0172</secondary_id>
    <nct_id>NCT02514083</nct_id>
  </id_info>
  <brief_title>A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL</brief_title>
  <official_title>A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot phase 2 study investigating the safety and efficacy of ibrutinib combined&#xD;
      with short-course fludarabine in previously untreated CLL patients. Ibrutinib will be given&#xD;
      daily until disease progression or intolerable side effects occur. Fludarabine will be given&#xD;
      in cycles 3 and 4. The primary efficacy endpoint is the rate of complete response after 6&#xD;
      cycles or 24 weeks. The primary safety endpoint is the rate of treatment discontinuation&#xD;
      after 6 cycles or 24 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) are tumors of B&#xD;
      cells that often affect elderly patients. While the cause of CLL is still unclear, studies&#xD;
      have indicated critical factors required for the tumor cells. First, CLL cells grow and&#xD;
      survive because they receive signals through the B-cell receptor (BCR); and second, CLL cells&#xD;
      benefit from interactions with other cells, especially T cells.&#xD;
&#xD;
      The stimulation through the BCR can be reduced with ibrutinib, which is an oral drug that&#xD;
      selectively inhibits Bruton's tyrosine kinase (BTK). In clinical trials, ibrutinib&#xD;
      demonstrated safety and high response rates in patients with high-risk disease. Ibrutinib has&#xD;
      gained FDA approval as a treatment for CLL patients with 17p deletion and for those who had&#xD;
      at least one prior therapy. However, single-agent ibrutinib has limitations; the drug does&#xD;
      not eliminate all the tumor cells, and, with time, the tumor cells may become resistant.&#xD;
      Therefore, a combination of ibrutinib with other drugs could be beneficial. Here we chose&#xD;
      fludarabine because it is a well-tolerated drug that has been used widely to treat CLL. Also,&#xD;
      fludarabine can kill both malignant B cells and T cells that support the growth of leukemia&#xD;
      cells. With this approach, we hope to restore a healthier immune system.&#xD;
&#xD;
      This study will investigate the safety and efficacy of ibrutinib combined with fludarabine.&#xD;
      This protocol is intended for previously untreated CLL patients. Ibrutinib will be given&#xD;
      daily until disease progression or intolerable side effects occur. Fludarabine will be given&#xD;
      only in cycles 3 and 4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 9, 2015</start_date>
  <completion_date type="Anticipated">February 4, 2023</completion_date>
  <primary_completion_date type="Actual">October 2, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Complete Response at 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of complete response at 24 weeks or after 6 cycles. Response assessment was conducted according to the guidelines from the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Treatment Discontinuation Within the First 24 Weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Rate of treatment discontinuation within the first 24 weeks or 6 cycles due to intolerable side effects from study therapy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Ibrutinib and short-course fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 420 mg PO daily for the duration of the study&#xD;
Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Ibrutinib 420mg PO daily for the duration of the study.</description>
    <arm_group_label>Ibrutinib and short-course fludarabine</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4</description>
    <arm_group_label>Ibrutinib and short-course fludarabine</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:&#xD;
&#xD;
          1. Men and women with histologically confirmed disease as defined by the following:&#xD;
&#xD;
               -  CLL: clonal B-lymphocytosis greater than or equal to 5,000 cells/microL .&#xD;
&#xD;
               -  SLL: lymphadenopathy with the tissue morphology of CLL but that are not leukemic,&#xD;
                  &lt; 5,000 cells/microL.&#xD;
&#xD;
               -  Immunophenotypic profile or immunohistochemistry read by an expert pathologist as&#xD;
                  consistent with CLL. This will include CD5, CD19, and CD20 expression by the CLL&#xD;
                  cells typically also with CD23 expression, but CD23 negative cases may be&#xD;
                  included if there is an absence of t(11;14).&#xD;
&#xD;
          2. Active disease as defined by at least one of the following (IWCLL consensus criteria):&#xD;
&#xD;
               -  Weight loss greater than or equal to 10% within the previous 6 months&#xD;
&#xD;
               -  Extreme fatigue&#xD;
&#xD;
               -  Fevers of greater than 100.5 F for greater than or equal to 2 weeks without&#xD;
                  evidence of infection&#xD;
&#xD;
               -  Night sweats for more than one month without evidence of infection&#xD;
&#xD;
               -  Evidence of progressive marrow failure as manifested by the development of, or&#xD;
                  worsening of, anemia and/or thrombocytopenia&#xD;
&#xD;
               -  Massive or progressive splenomegaly&#xD;
&#xD;
               -  Massive nodes or clusters or progressive lymphadenopathy&#xD;
&#xD;
               -  Progressive lymphocytosis with an increase of &gt;50% over a 2-month period, or an&#xD;
                  anticipated doubling time of less than 6 months&#xD;
&#xD;
          3. Treatment naive CLL/SLL patients&#xD;
&#xD;
             -Treatment-naive CLL indicates no prior anti-CLL therapy. Anti-CLL therapy includes&#xD;
             chemotherapies, monoclonal antibodies, and targeted agents with known or reasonably&#xD;
             expected anti-leukemic activity.&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to&#xD;
             2&#xD;
&#xD;
          5. Absolute neutrophil count (ANC) &gt; 750/microL, platelets &gt; 50,000/microL&#xD;
&#xD;
          6. Agreement to use acceptable methods of contraception during the study and for 90 days&#xD;
             after the last dose of study drug if sexually active and able to bear or beget&#xD;
             children. Female subjects of childbearing potential must have a negative serum&#xD;
             pregnancy test upon study entry. Male and female subjects who agree to use both a&#xD;
             highly effective method of birth control (eg, implants, injectables, combined oral&#xD;
             contraceptives, some intrauterine devices, complete abstinence, or sterilized partner)&#xD;
             and a barrier method (e.g. condoms, vaginal ring, sponge, etc.) during the period of&#xD;
             therapy and for 90 days after the last dose of study drug.&#xD;
&#xD;
          7. Willing and able to participate in all required evaluations and procedures in this&#xD;
             study protocol including swallowing capsules without difficulty&#xD;
&#xD;
          8. Ability to understand the purpose and risks of the study and provide signed and dated&#xD;
             informed consent and authorization to use protected health information (in accordance&#xD;
             with national and local subject privacy regulations)&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
          1. Transformed CLL, including Hodgkin and non-Hodgkin lymphoma&#xD;
&#xD;
          2. Active autoimmune hemolytic anemia or thrombocytopenia&#xD;
&#xD;
          3. Known bleeding disorders&#xD;
&#xD;
          4. Impaired hepatic function: Total bilirubin greater than or equal to 1.5 times upper&#xD;
             limit of normal unless due to Gilbert's disease, aspartate aminotransferase (AST) or&#xD;
             alanine transaminase (ALT) greater than or equal to 2.5 times institutional upper&#xD;
             limit of normal unless due to infiltration of liver, Child-Pugh class B or C&#xD;
&#xD;
          5. Impaired renal function: estimated glomerular filtration rate (GFR) &lt;&#xD;
             30ml/min/1.73m(2) based on CKD-EPI&#xD;
&#xD;
          6. Life-threatening illness, medical condition or organ system dysfunction which, in the&#xD;
             investigators opinion, could compromise the subject's safety, interfere with the&#xD;
             absorption or metabolism of ibrutinib and fludarabine, or put the study outcomes at&#xD;
             undue risk&#xD;
&#xD;
          7. Concomitant immunomodulatory therapy, chemotherapy, radiotherapy or experimental&#xD;
             therapy&#xD;
&#xD;
          8. Active Hepatitis B or Hepatitis C infection&#xD;
&#xD;
          9. HIV infection&#xD;
&#xD;
         10. Female patients who are currently in pregnancy, or unwilling to use acceptable methods&#xD;
             of contraception or refrain from pregnancy if of childbearing potential or currently&#xD;
             breastfeeding. Male patients who are unwilling to follow the contraception&#xD;
             requirements described in this protocol.&#xD;
&#xD;
         11. Psychiatric illness/social situations that would limit the patient's ability to&#xD;
             tolerate and/or comply with study requirements.&#xD;
&#xD;
         12. Unable to understand the investigational nature of the study or give informed consent.&#xD;
&#xD;
         13. Individuals &lt; 18 years old&#xD;
&#xD;
         14. Known hypersensitivity to any component of ibrutinib or fludarabine&#xD;
&#xD;
         15. Requires concomitant anticoagulation with Coumadin (warfarin) or other vitamin K&#xD;
             antagonists.&#xD;
&#xD;
         16. Prior malignancy, except for adequately treated basal cell or squamous cell skin&#xD;
             cancer, in situ cervical cancer, or other cancer from which the subject has been&#xD;
             disease-free for greater than or equal to 2 years or which will not limit survival to&#xD;
             &lt; 2 years&#xD;
&#xD;
         17. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or&#xD;
             resection of the stomach or small bowel or ulcerative colitis, symptomatic&#xD;
             inflammatory bowel disease, or partial or complete bowel obstruction&#xD;
&#xD;
         18. History of stroke or intracranial hemorrhage within 6 months before the first dose of&#xD;
             study drug&#xD;
&#xD;
         19. Major surgery within 4 weeks of first dose of study drug&#xD;
&#xD;
         20. Currently active, clinically significant cardiovascular disease such as uncontrolled&#xD;
             or symptomatic arrhythmias, Class 3 or 4 congestive heart failure as defined by New&#xD;
             York Heart Association Functional Classification, or a history of myocardial&#xD;
             infarction or unstable angina, or acute coronary syndrome within 6 months of&#xD;
             screening.&#xD;
&#xD;
         21. Subjects who received a strong cytochrome P450 (CYP) 3A inhibitor within 7 days prior&#xD;
             to the first dose of ibrutinib or subjects who require continuous treatment with a&#xD;
             strong CYP3A inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Inhye Ahn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2015-H-0172.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <results_first_submitted>August 26, 2020</results_first_submitted>
  <results_first_submitted_qc>September 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 8, 2020</results_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruton's tyrosine kinase inhibitor</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Immune modulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02514083/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ibrutinib With Fludarabine in Patients With CLL or SLL</title>
          <description>Open-label study of ibrutinib and a short-course fludarabine in previously untreated participants with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Ibrutinib is administered orally, 420 mg daily for duration of study. Fludarabine dose is 25 mg/m2/day on days 1-5 of cycles 3 and 4.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibrutinib With Fludarabine in Patients With CLL or SLL</title>
          <description>Open-label study of ibrutinib and a short-course fludarabine in previously untreated participants with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Ibrutinib is administered orally, 420 mg daily for duration of study. Fludarabine dose is 25 mg/m2/day on days 1-5 of cycles 3 and 4.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.4" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Complete Response at 24 Weeks</title>
        <description>Rate of complete response at 24 weeks or after 6 cycles. Response assessment was conducted according to the guidelines from the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL).</description>
        <time_frame>24 weeks</time_frame>
        <population>Treatment-naive CLL or SLL patients</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib With Fludarabine in Patients With CLL or SLL</title>
            <description>Open-label study of ibrutinib and a short-course fludarabine in previously untreated participants with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Ibrutinib is administered orally, 420 mg daily for duration of study. Fludarabine dose is 25 mg/m2/day on days 1-5 of cycles 3 and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Complete Response at 24 Weeks</title>
          <description>Rate of complete response at 24 weeks or after 6 cycles. Response assessment was conducted according to the guidelines from the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL).</description>
          <population>Treatment-naive CLL or SLL patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial response with or without lymphocytosis</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Treatment Discontinuation Within the First 24 Weeks</title>
        <description>Rate of treatment discontinuation within the first 24 weeks or 6 cycles due to intolerable side effects from study therapy</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibrutinib With Fludarabine in Patients With CLL or SLL</title>
            <description>Open-label study of ibrutinib and a short-course fludarabine in previously untreated participants with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Ibrutinib is administered orally, 420 mg daily for duration of study. Fludarabine dose is 25 mg/m2/day on days 1-5 of cycles 3 and 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Treatment Discontinuation Within the First 24 Weeks</title>
          <description>Rate of treatment discontinuation within the first 24 weeks or 6 cycles due to intolerable side effects from study therapy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Treatment discontinued within 24 weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Treatment continued for 24+ weeks</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From treatment initiation until the last follow-up on study or death, whichever occurred first, assessed up to 4 years</time_frame>
      <desc>The AE reporting period for this study begins when the participant takes the first dose of study drug and continues until the last follow-up on the study. Participants will continue on study until disease progression or intolerable side effects occur.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibrutinib With Fludarabine in Patients With CLL or SLL</title>
          <description>Open-label study of ibrutinib and a short-course fludarabine in previously untreated participants with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Ibrutinib is administered orally, 420 mg daily for days 1-28 from Cycle 1 up to Cycle 27. Fludarabine dose is 25 mg/m2/day on days 1-5 of cycles 3 and 4.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE version 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post-operative Hemorrhage (Epistaxis)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Vulvar intraepithelial neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Triple negative Breast Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Papillary Thyroid Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE version 4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Peripheral edema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Shingles</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Infections and infestations: other</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Platelet count decresaed</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Neutrophil count decresaed</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Alanine or aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Brittle nails</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Maculopapular rash</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Inhye Ahn, M.D.</name_or_title>
      <organization>National Heart Lung and Blood Institute (NHLBI)</organization>
      <phone>301-827-1203</phone>
      <email>inhye.ahn@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

